Pulmonary fibrosis progresses at widely different rates depending on the type, but the most common and aggressive form, idiopathic pulmonary fibrosis (IPF), carries a median survival of 3 to 5 years from diagnosis. Untreated patients typically lose about 150 to 200 mL of lung capacity per year, though some people remain stable for years while others decline rapidly over months. Understanding what drives that variation can help you make sense of your own situation or a loved one’s prognosis.
Typical Rate of Lung Function Decline
Doctors track progression primarily through a breathing test called forced vital capacity (FVC), which measures how much air you can push out in one full breath. In IPF, the median decline is roughly 65 mL per year, though this number comes from patients already receiving treatment or enrolled in clinical trials, where milder cases are overrepresented. Real-world decline in untreated patients often runs higher, closer to 150 to 200 mL per year in many studies. To put that in perspective, a healthy adult lung holds about 4,000 to 5,000 mL of air. Losing 150 mL a year may not sound like much, but because fibrosis also stiffens the lung tissue and impairs oxygen transfer, the functional impact is far greater than the raw numbers suggest.
What makes pulmonary fibrosis especially unpredictable is that it doesn’t always decline in a smooth, steady line. Some people experience a slow, gradual worsening over years. Others hold relatively steady and then drop sharply. That sharp drop often comes from an acute exacerbation, which is covered below.
How Different Types Compare
IPF is the fastest-progressing form of pulmonary fibrosis, but it’s not the only one. Lung scarring can also develop from autoimmune diseases, chronic allergic reactions (hypersensitivity pneumonitis), medications, and other causes. These non-IPF forms are collectively called interstitial lung diseases (ILDs), and many of them progress slowly or even stabilize with treatment of the underlying condition.
The critical turning point is when any of these conditions develops a “progressive fibrotic phenotype,” meaning the scarring starts behaving like IPF: worsening despite treatment. Clinicians estimate this shift happens roughly 11 to 15 months after the initial ILD diagnosis in patients who do progress. Once that progressive pattern is established, survival looks similar to IPF, with an estimated 30 to 45 months from the onset of progressive scarring to death. Before that turning point, non-IPF forms generally carry a significantly better prognosis than IPF.
Acute Exacerbations: Sudden Worsening
One of the most dangerous features of progressive pulmonary fibrosis is the acute exacerbation, a sudden flare of worsening breathlessness that develops over days to weeks, with new areas of inflammation visible on chest imaging. These episodes are not rare. In a study following patients with progressive fibrosis over a median of about three years, nearly a third experienced at least one acute exacerbation. The one-year incidence was 12.5%, climbing to 38% by five years.
Acute exacerbations have an outsized impact on survival. Patients who experienced one had a median survival of 30 months after their progressive fibrosis diagnosis, while those who avoided exacerbations had not yet reached a median survival point during the same follow-up period. An exacerbation roughly doubled the risk of death even after accounting for other factors like age and baseline lung function. These flares can be triggered by infections, aspiration, or air pollution, but in many cases no clear trigger is identified.
What Predicts Faster Progression
Several factors help doctors estimate how quickly an individual case will move. The GAP index, one of the most widely used prediction tools for IPF, scores four variables: sex (male carries higher risk), age (especially over 65), lung capacity on breathing tests, and the lung’s ability to transfer oxygen into the blood. Higher scores correspond to higher mortality risk over the next one to three years.
CT imaging offers another powerful clue. The extent of honeycombing, a pattern of small, clustered air pockets that represents end-stage scarring, independently predicts survival. Patients whose honeycombing covered 4.8% or more of their lung volume had a median survival of just 1.3 years, compared to 5.0 years for those below that threshold. The presence of a honeycomb pattern on CT is one of the strongest single indicators of rapid decline.
Genetics also play a role. A common variant in a gene called MUC5B is associated with greater extent of fibrosis and features of the most aggressive scarring pattern. Separately, people with shorter telomeres (the protective caps on chromosomes, which naturally shorten with age) tend to develop more severe scarring and have reduced survival. Telomere length below the tenth percentile for a person’s age is significantly linked to worse outcomes. These genetic factors aren’t routinely tested in every patient, but they help explain why two people with the same diagnosis can follow very different trajectories.
Blood markers also provide prognostic information. A protein called KL-6, released by damaged lung cells, has been studied as a predictor. Patients with initial KL-6 levels above 1,000 U/mL had a median survival of only 18 months, compared to more than 36 months for those with lower levels. This kind of blood test can help identify people at risk for faster progression early in the disease.
How Treatment Affects the Timeline
Two antifibrotic medications are currently approved for pulmonary fibrosis. The better-studied of the two, nintedanib, approximately halves the rate of lung function decline. Across four major clinical trials covering different types of pulmonary fibrosis, it reduced the annual loss of lung capacity by about 51% compared to placebo. The effect was consistent whether patients had IPF or other progressive fibrotic lung diseases, ranging from a 44% to 61% reduction depending on the population studied.
It’s important to understand what “slowing decline” means in practice. These medications do not stop fibrosis or reverse existing scarring. They stretch out the timeline, potentially adding months to years of preserved function and quality of life, but the disease continues to progress. Some studies have found that the measured decline in patients taking antifibrotics still closely resembles the natural course of the disease in certain subgroups, suggesting that individual response varies considerably. Lung transplant remains the only intervention that can fundamentally change the survival trajectory for eligible patients.
What Progression Feels Like Over Time
In the earliest stages, pulmonary fibrosis often causes breathlessness only during exercise or exertion. Many people attribute it to aging or being out of shape, which is one reason diagnosis is frequently delayed. As lung capacity drops and oxygen transfer worsens, everyday activities like climbing stairs, carrying groceries, or walking across a parking lot become noticeably harder.
Over the following months to years, a persistent dry cough typically develops or worsens. Fatigue becomes a constant companion, partly from the effort of breathing and partly from lower oxygen levels. Eventually, supplemental oxygen becomes necessary, first during activity and later at rest. The timeline for reaching this point varies enormously. Some patients need oxygen within a year of diagnosis, while others manage without it for several years. The transition to needing oxygen during daily activities is often the change that most affects quality of life and independence.
As the disease advances further, pulmonary hypertension (high blood pressure in the lung’s blood vessels) can develop as the heart works harder to push blood through scarred lung tissue. This adds right-sided heart strain to the picture and can accelerate decline. Weight loss, finger clubbing (a rounding of the fingertips), and increasingly limited mobility mark the later stages of the disease.